Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril, quantity: 1.25 mg - capsule - excipient ingredients: pregelatinised maize starch; hydrophobic colloidal silica anhydrous; titanium dioxide; purified water; iron oxide yellow; gelatin; sodium lauryl sulfate - - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. - post mi heart failure, - prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. - for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. - for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril, quantity: 10 mg - capsule - excipient ingredients: hydrophobic colloidal silica anhydrous; pregelatinised maize starch; titanium dioxide; purified water; gelatin; sodium lauryl sulfate; brilliant scarlet 4r; patent blue v - - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. - post mi heart failure, - prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. - for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. - for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril, quantity: 1.25 mg - capsule - excipient ingredients: pregelatinised maize starch; hydrophobic colloidal silica anhydrous; titanium dioxide; purified water; iron oxide yellow; gelatin; sodium lauryl sulfate - - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. - post mi heart failure, - prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. - for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. - for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Canada - English - Health Canada

pharmascience inc - ramipril; hydrochlorothiazide - tablet - 10.0mg; 12.5mg - ramipril 10.0mg; hydrochlorothiazide 12.5mg - angiotensin-converting enzyme inhibitors

Canada - English - Health Canada

pharmascience inc - ramipril; hydrochlorothiazide - tablet - 10.0mg; 25.0mg - ramipril 10.0mg; hydrochlorothiazide 25.0mg - angiotensin-converting enzyme inhibitors

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ramipril, quantity: 2.5 mg - capsule - excipient ingredients: erythrosine; iron oxide yellow; lactose monohydrate; gelatin; titanium dioxide; magnesium stearate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - ? treatment of hypertension. (data are currently not available to support the use of ramipril in renovascular hypertension).,? post mi heart failure.,? prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day.,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease.,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mm hg or diastolic blood pressure > 90 mm hg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l; hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ramipril, quantity: 5 mg - capsule - excipient ingredients: erythrosine; gelatin; indigo carmine; titanium dioxide; magnesium stearate; lactose monohydrate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - ? treatment of hypertension. (data are currently not available to support the use of ramipril in renovascular hypertension).,? post mi heart failure.,? prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day.,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease.,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mm hg or diastolic blood pressure > 90 mm hg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l; hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ramipril, quantity: 10 mg - capsule - excipient ingredients: lactose monohydrate; gelatin; erythrosine; iron oxide black; indigo carmine; magnesium stearate; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; ethanol; shellac; sulfuric acid - ? treatment of hypertension. (data are currently not available to support the use of ramipril in renovascular hypertension).,? post mi heart failure.,? prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day.,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease.,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mm hg or diastolic blood pressure > 90 mm hg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l; hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ramipril, quantity: 1.25 mg - capsule - excipient ingredients: lactose monohydrate; gelatin; titanium dioxide; iron oxide yellow; magnesium stearate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - ? treatment of hypertension. (data are currently not available to support the use of ramipril in renovascular hypertension).,? post mi heart failure.,? prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day.,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease.,? for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure > 160 mm hg or diastolic blood pressure > 90 mm hg (or on antihypertensive treatment); total cholesterol > 5.2 mmol/l; hdl cholesterol < 0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - ramipril -